Description:This volume, p53, was developed primarily as a resource for access to key ideas in the field that have developed over the years including how transgenics have been used to study p53, how clinical genetics have identified and studied mutations in p53 found in human cancers, how p53 can be regulated by post-translational modification, and how key drug targets have been defined, namely MDM2, which has provided fundamental approaches for defining how p53 can be activated with potentially therapeutic effect. The key concepts in the chapters included provide a perspective on key paradigms in the p53 field.